Literature DB >> 14511004

Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen.

C-H Yang1, H-C Ho, Y-S Chan, L-B Liou, H-S Hong, L-C Yang.   

Abstract

We describe a new method for treating livedoid vasculopathy. The typical presentation of livedoid vasculopathy includes chronic, recurrent painful ulcers, satellite scar-like atrophy and telangiectasia involving the lower extremities. Histologically, these lesions show areas of ulceration and dermal vessel occlusion without frank inflammatory cell infiltration. There is currently no satisfactory therapy available for this disease. Hyperbaric oxygen (HBO) has recently established itself as one of the most effective methods of treating ischaemic wounds, including diabetic ulcers. We used this therapy in two patients whose lesions were resistant to multiple therapeutic modalities. Not only did their ulcers respond rapidly to the HBO therapy, but the disturbing wound pain also resolved at the same time. To our knowledge, this is the first successful trial of HBO therapy in livedoid vasculopathy. We believe this to be a very promising new therapy for livedoid vasculopathy and to be worth further investigation.

Entities:  

Mesh:

Year:  2003        PMID: 14511004     DOI: 10.1046/j.1365-2133.2003.05546.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

1.  [Livedoid vasculopathy with heterozygous factor V Leiden mutation and sticky platelet syndrome].

Authors:  V Lewerenz; T Burchardt; A Büchau; T Ruzicka; M Megahed
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

2.  Livedoid vasculopathy managed with hyperbaric oxygen therapy.

Authors:  Sourabh Bhutani; Rohit Verma; George Verghese
Journal:  Med J Armed Forces India       Date:  2012-07-17

Review 3.  Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.

Authors:  Asli Bilgic; Salih Ozcobanoglu; Burcin Cansu Bozca; Erkan Alpsoy
Journal:  Int J Womens Dermatol       Date:  2021-09-02

4.  Livedoid Vasculopathy with Hyperhomocysteinemia Responding to Hyperbaric Oxygen Therapy.

Authors:  Rahul Ray; Aseem Sharma; Biju Vasudevan; Jandhyala Sridhar; Rajeev Deo; C S Mohanty
Journal:  Indian J Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.494

Review 5.  From dermatological conditions to COVID-19: Reasoning for anticoagulation, suppression of inflammation, and hyperbaric oxygen therapy.

Authors:  Paulo Ricardo Criado; Hélio Amante Miot; Thais Prota Hussein Pincelli; Alexandre Todorovic Fabro
Journal:  Dermatol Ther       Date:  2020-11-30       Impact factor: 3.858

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.